[Estrogen, hormonal therapy and Aging]

Area of Science:

• Reproductive Endocrinology
• Cardiovascular Health
• Pharmacology

Context:

• Menopause marks a critical transition in women's health, influencing long-term disease risk.
• The
• window of opportunity
• for hormone replacement therapy (HRT) initiation is increasingly recognized.
• Emerging evidence differentiates synthetic and physiological hormones, impacting therapeutic choices.

Purpose:

• To evaluate the optimal timing and formulation of HRT for mitigating mortality and coronary heart disease (CHD) risks in postmenopausal women.
• To compare the safety and efficacy profiles of different HRT components and delivery systems.
• To underscore the importance of personalized HRT regimens based on individual health profiles.

Summary:

• Initiating HRT between ages 50-59 or within 10 years of menopause onset is associated with reduced mortality and CHD risk.
• Physiological estradiol, especially via non-oral routes, demonstrates a favorable safety profile, with the lowest thrombosis risk.
• Natural progesterone appears neutral regarding breast cancer risk and preserves estrogen's benefits for the nervous system and vasculature.

Impact:

• Provides evidence-based guidance for optimizing HRT strategies in menopausal women.
• Highlights the potential for HRT to improve long-term health outcomes, including cardiovascular health.
• Emphasizes the need for personalized medicine in hormone therapy, considering individual risk factors and patient preferences.